

Equity Research

February 5, 2016

Mark Palmer

(212) 588-6582 mpalmer@btig.com

Giuliano Bologna

(212) 588-6583 gbologna@btig.com

GNW	\$2.79
12 month target	\$5.00

BUY

 52 week range
 \$2.22 - \$9.15

 Market Cap (m)
 \$1,389



Financials

Genworth Financial, Inc.

4Q15 Report Positives Overshadowed by Suspension of Life, Annuity Sales; Reducing PT to \$5 (from \$10)

The headlines arising from Genworth Financial's (GNW) 4Q15 report have inevitably focused on the company's decision to suspend all sales of traditional life insurance and fixed annuity products this quarter given the impact of the company's below investment grade credit ratings as reflected in recent sales volumes. However, we believe that move is overshadowing several of the positives emerging from GNW's report, most notably much-needed stability in the results of its troubled long-term care (LTC) unit as well as its Australia and Canada mortgage insurance units.

- ▶ We are reiterating our Buy recommendation on GNW while reducing our price target to \$5 (from \$10) based on 0.25x its FY16E book value ex. accumulated other comprehensive income (AOCI) of \$20.07. While the company faces significant challenges, we believe their impact is already reflected in a stock trading at just 0.14x its book value per share ex. AOCI as of YE15. Moreover, GNW's more than \$1bn in estimated liquidity − liquidity of \$1.374bn as of YE15, net of the \$321mm it used to retire an issue of senior notes last month − helps to preserve optionality as the company proceeds with its efforts to unlock value, in our view.
- ▶ Those efforts will begin with the source of GNW's most significant challenges –its LTC unit as management announced it would initiate a restructuring of its U.S. Life business aimed at separating and isolating LTC. We believe this is a prudent and necessary step for the company to take, particularly if management's end-game strategy is to split-up the company, which would help to unlock its inherent value, led by the value of its U.S. mortgage insurance unit.
- We believe isolating LTC will be much easier for GNW if the unit's (continued on page 2)
- ▶ Valuation: Our price target of \$5.00 is based on 0.25X our FY16E book value (ex-AOCI) per share of \$20.07

Estimates

	1Q15 A	2Q15 A	3Q15 A	4Q15 A	FY15 A	1Q16 E	2Q16 E	3Q16 E	4Q16 E	FY16 E	FY17 E
Diluted EPS (Adj.)	0.31	(0.39)	(0.57)	(0.59)	(1.24)	0.21	0.22	0.23	0.24	0.90	0.94
BVPS (Ex-AOCI)	21.31	20.77	20.31	19.72	19.69	19.59	19.72	19.86	20.01	20.07	20.46
Operating Income	295	245	(351)	(203)	(14)	222	230	236	242	931	964

Source: BTIG Research Estimates and Company Documents (\$ in millions, except per share amount)



(continued from page 1)

operating performance is stable, which it was during 4Q15. The unit posted net operating income of \$19mm during the quarter, its third profitable quarter in the past four.

- ▶ Meanwhile, the company's three mortgage insurance units each delivered solid performances during 4Q15 in the midst of an uncertain environment. The U.S. mortgage insurance unit posted net operating income of \$41mm, up sequentially from \$37mm. That result is significant insofar as it demonstrated that GNW's issues as a company are apparently not having a negative impact on its mortgage insurance operations in the U.S., which is by no means a given in light of significant competition in the space.
- ▶ At the same time, GNW's Australia and Canada units both performed well during 4Q15, results that were reassuring given the dependence of those countries on commodities, the prices of which have plunged of late. The Australian unit reported net operating income of \$22mm during the quarter, up by \$1mm sequentially, while the Canadian unit posted net operating income of \$37mm, down by just \$1mm sequentially. Somewhat remarkably, the Australian unit's loss ratio declined by 12 points sequentially to 17%. The Canadian unit's loss ratio increased by a relatively modest 2% to 3%.
- ▶ GNW reported 4Q15 adjusted operating income per share of \$0.20, in line with the consensus estimate while outpacing our estimate of \$0.17. However, the company did take a hit to its book value during the quarter as it revised assumptions in its Universal Life business line related to persistency, mortality and long-term interest rates that translated into an after-tax charge of \$194mm. As a consequence, GNW's book value ex. AOCI declined by \$0.59 per share sequentially during the quarter.
- by the rationale of Standard & Poor's when it downgraded the company's credit ratings to junk levels in November 2014—which was that the move was based on volatility in that unit. As such, we believe that the company's actions could result not only in higher credit ratings, but also in more strategic flexibility—particularly with regard to a potential split—than it currently has.
- ▶ We appreciate that some investors regard GNW as a survival game at this point, and while we acknowledge the company's challenges, we also believe investors should regard its optionality thanks to its liquidity and the fact that several of its units are discrete and capable of monetization. One factor we believe should be recognized is that companies such as GNW are not banks and therefore are not susceptible to the same "run" challenges as such financial institutions—a distinction that we believe has been overlooked as the Financials space has sold off during the past few weeks.



Income Statement

Genworth Financial Operating Model	Dec-13	Mar-14	Jun-14	Sep-14	Dec-14	Dec-14	Mar-15	Jun-15	Sep-15	Dec-15	Dec-15	Mar-16	Jun-16	Sep-16	Dec-16	Dec-16	Dec-17
\$ millions	2013A	1Q14A	2Q14A	3Q14A	4Q14A	2014A	1Q15A	2Q15A	3Q15A	4Q15A	2015A	1Q16E	2Q16E	3Q16E	4Q16E	2016E	2017E
Premiums	5,148	1,307	1,343	1,395	1,386	5,431	1323	1134	1145	1157	4,759	1151	1165	1202	1226	4,745	4,816
Net investment income	3,271	805	813	805	819	3,242	803	793	783	781	3,160	811	801	803	808	3,223	3,255
Net investment gains (losses)	(37)	(17)	34	(27)	(10)	(20)	-16	8	-51	-16	(75)	0	0	0	0	-	-
Insurance and investment product fees and other	1,021	227	225	231	229	912	225	222	223	234	904	227	224	225	236	913	922
Total revenues	9,403	2,322	2,415	2,404	2,424	9,565	2,335	2,157	2,100	2,156	8,748	2,189	2,190	2,230	2,271	8,881	8,993
Benefits and other changes in policy reserves	4,895	1,194	1,256	1,986	2,184	6,620	1243	1232	1290	1435	5,200	1181	1214	1251	1162	4,808	4,856
Interest credited	738	183	184	185	185	737	180	181	179	180	720	184	185	188	182	738	745
Acquisition and operating expenses, net of deferrals	1,659	378	404	398	405	1,585	380	295	314	433	1,422	361	354	345	424	1,485	1,500
Amortization of deferred acquisition costs and intangibles	569	134	138	143	156	571	121	101	563	207	992	123	103	103	155	485	490
Goodwill impairment	-	-	-	550	299	849	-	-	-	-	-	0	0	0	0	-	-
Interest expense	492	127	120	114	118	479	116	103	105	104	428	118	105	106	105	434	439
Total Benefits and Expenses	8,353	2,016	2,102	3,376	3,347	10,841	2,040	1,912	2,451	2,359	8,762	1,967	1,960	1,994	2,029	7,950	8,029
Income before income taxes	1,050	306	313	(972)	(923)	(1,276)	295	245	(351)	(203)	(14)	222	230	236	242	931	964
Provision for income taxes	324	87	85	(185)	(215)	(228)	91	70	(134)	(36)	(9)	67	69	71	73	279	289
Tax rate	30.9%	28.4%	27.2%	19.0%	23.3%	17.9%	30.8%	28.6%	38.2%	17.7%	64.3%	30.0%	30.0%	30.0%	30.0%	30.0%	30.0%
Net income (loss)	726	219	228	(787)	(708)	(1,048)	204	175	(217)	(167)	(5)	155	161	165	170	652	675
Income (loss) from discontinued operations	-	-	-	-	-	-	-	(314)	(21)	(73)	(408)	-	-	-	-	-	-
Less: net income attributable to noncontrolling interests	152	35	52	57	52	196	50	54	46	52	202	50	50	50	50	200	200
Net income (loss) available to common stockholders	574	184	176	(844)	(760)	(1,244)	154	(193)	(284)	(292)	(207)	105	111	115	120	452	475
Earnings per share - diluted	\$1.15	\$0.37	\$0.35	(\$1.70)	(\$1.53)	(\$2.51)	\$0.31	(\$0.39)	(\$0.57)	(\$0.59)	(\$1.24)	\$0.21	\$0.22	\$0.23	\$0.24	\$0.90	\$0.94
Net operating income per share - diluted	\$1.24	\$0.37	\$0.31	(\$0.65)	(\$0.83)	(\$0.80)	\$0.31	\$0.24	\$0.13	(\$0.17)	\$0.51	\$0.21	\$0.22	\$0.23	\$0.24	\$0.90	\$0.94
Total stockholders' equity, excluding AOCI	11,891	12,032	12,243	11,231	10,477	10,477	10,632	10,381	10,101	9,814	9,814	9,794	9,881	9,971	10,066	10,066	10,340
Total AOCI	2,542	3,483	4,215	3,934	4,446	4,546	4,692	3,309	3,478	3,010	3,110	3,135	3,160	3,185	3,210	3,310	3,510
Total stockholders' equity	14,812	15,515	16,458	15,165	14,923	14,923	15,324	13,690	13,579	12,824	12,824	12,929	13,041	13,156	13,276	13,276	13,750
Book value per share	\$29.55	\$31.27	\$32.68	\$30.54	\$30.04	\$30.04	\$30.72	\$27.39	\$27.30	\$25.77	\$25.73	\$25.86	\$26.03	\$26.21	\$26.39	\$26.47	\$27.20
Book value per share (excluding AOCI)	\$23.73	\$24.25	\$24.31	\$22.62	\$21.09	\$21.09	\$21.31	\$20.77	\$20.31	\$19.72	\$19.69	\$19.59	\$19.72	\$19.86	\$20.01	\$20.07	\$20.46
Weighted average diluted shares	501.2	502.7	503.6	496.6	496.7	499.9	498.9	499.9	497.4	497.6	498.5	500.0	501.0	502.0	503.0	501.5	505.5

Source: BTIG Research Estimates and Company Documents



Appendix: Analyst Certification and Other Important Disclosures

Analyst Certification

I, Mark Palmer, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

I, Giuliano Bologna, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

Regulatory Disclosures

Analyst Stock Ratings Definitions

BTIG LLC's ("BTIG") ratings, effective May 10, 2010, are defined as follows:

BUY – A stock that is expected at initiation to produce a positive total return of 15% or greater over the 12 months following the initial recommendation. The BUY rating may be maintained following initiation as long as it is deemed appropriate, notwithstanding price fluctuations that would cause the target to fall outside of the 15% return.

SELL – A stock that is expected at initiation to produce a negative total return of 15% or greater over the next 12 months following the initial recommendation. The SELL rating may be maintained following initiation as long as it is deemed appropriate, notwithstanding price fluctuations that would cause the target to fall outside of the 15% return.

NEUTRAL – A stock that is not expected to appreciate or depreciate meaningfully over the next 12 months. **NOT RATED** – A stock that is not rated but that is covered by BTIG.

Distribution of Ratings and Investment Banking Clients

BTIG must disclose in each research report the percentage of all securities rated by the member to which the member would assign a "buy", "neutral" or "sell" rating. The said ratings are updated on a quarterly basis. BTIG must also disclose the percentage of subject companies within each of these three categories for whom the member has provided investment banking services within the previous twelve months. Stocks under coverage as of the end of the most recent calendar quarter (December 31, 2015): 186

Distribution of BTIG's Research Recommendations (as of December 31, 2015):

BUY: 64.5%; NEUTRAL: 31.7%; SELL: 3.8%

Distribution of BTIG's Investment Banking Services (as of December 31, 2015):

BUY: 89%; NEUTRAL: 5.5%; SELL: 5.5%


For purposes of FINRA ratings distribution rules, BTIG's stock ratings of Buy, Neutral and Sell fall into Buy, Hold and Sell categories, respectively.

Company Valuation and Risk Disclosures

Genworth Financial, Inc. (GNW, Buy)

Valuation: Our price target of \$5.00 is based on 0.25X our FY16E book value (ex-AOCI) per share of \$20.07 **Risks:** The primary risks to achieving our price target include an accelerated rate of deterioration within GNW's U.S. Mortgage Insurance portfolio, credit downgrades that could hamper new business generation in all segments, a slowdown in the Chinese economy that could negatively affect the company's mortgage insurance units in commodity-focussed Australia and Canada, tail risk associated with the company's Long-Term care exposures, and reinvestment risk given the current low interest rate environment.





Dec-12 Mar-13 Jun-13 Sep-13 Dec-13 Mar-14 Jun-14 Sep-14 Dec-14 Mar-15 Jun-15 Sep-15 Dec-15

Note: Closing Price and Target Price have been adjusted for corporate actions.

Date	Closing Price (\$)	Target Price (\$)	Analyst	Rating
11-Apr-12	7.54	11	Mark Palmer	Buy
08-May-13	10.68		Mark Palmer	Neutral
08-Oct-13	12.62	17.50	Mark Palmer	Buy
04-Feb-14	14.53	18	Mark Palmer	Buy
24-Mar-14	17.93	22	Mark Palmer	Buy
06-Nov-14	8.66	16	Mark Palmer	Buy
11-Feb-15	8.33	15	Mark Palmer	Buy
10-Aug-15	5.24	13	Mark Palmer	Buy
30-Oct-15	4.87	10	Mark Palmer	Buy

Other Disclosures

Additional Information Available Upon Request

General Disclosures

Research reports produced by BTIG LLC ("BTIG") are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report.

The equity research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues.

BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice.

This research report is not an offer to buy or sell or solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. This research report was not drafted specifically for any particular individual or entity and is not a personal recommendation to participate in any particular trading strategy or transaction. Any recipient of this research report should obtain independent advice specific to their



personal circumstances before undertaking any investment activity and must make their own independent evaluation of any securities or financial instruments.

Facts, views or opinions presented in this report have not been reviewed by, and may not reflect information known to, employees or other professionals in the "BTIG Group" (BTIG Group includes, but is not limited to, BTIG and its parents, subsidiaries and/or affiliates). BTIG Group employees, including Sales Representatives and Traders, may provide oral or written commentary or advice that may be inconsistent with the opinions and/or views expressed in this research report. BTIG Group employees and/or its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report.

Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies control. Recipient of the research reports should be aware that investments in equity securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company. Any investment in equity securities should be undertaken only upon consideration of issues relating to the recipient's overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions.

Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.

The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability of any damages of any kind relating to such data. The report or any portion hereof may not be reprinted, sold or redistributed without the written consent of BTIG. This report is intended only for use by the recipient. The recipient acknowledges that all research and analysis in this report are the property of BTIG and agrees to limit the use of all publications received from BTIG within his, or her or its, own company or organization. No rights are given for passing on, transmitting, re transmitting or reselling the information provided.

Jurisdiction and Dissemination

BTIG is a U.S. broker-dealer and member of FINRA and SIPC.

BTIG Australia Limited ACN 128 554 601, member of ASIC and ASX; BTIG Hong Kong Limited, an Exchange Participant of SEHK and licensed and regulated by the SFC; BTIG Ltd, member of the LSE, authorized and regulated by the FSA; and BTIG Singapore Pte Ltd, registered and licensed with MAS; are all separate but affiliated entities of BTIG. Unless governing law permits otherwise, you must contact a BTIG entity in your home jurisdiction for further information, or if you want to use our services in effecting a transaction.

Issues and approved for distribution in the UK and EEA by BTIG Ltd. to eligible counterparties and professional clients only. Issued and distributed in Australia to "wholesale clients" only by BTIG Australia Limited. In Singapore and Hong Kong, further information may be obtained from BTIG Singapore Pte Ltd and BTIG Hong Kong Limited, respectively.